Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis

Sven Jarius; Jette Lautrup Battistini Frederiksen; Patrick Waters; Friedemann Paul; Gulsen Akman-Demir; Romain Marignier; Diego Franciotta; Klemens Ruprecht; Bettina Kuenz; Paulus Rommer; Wolfgang Kristoferitsch; Brigitte Wildemann; Angela Vincent

doi:10.1016/j.jns.2010.07.011

Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis

Sven Jarius, Jette Lautrup Battistini Frederiksen, Patrick Waters, Friedemann Paul, Gulsen Akman-Demir, Romain Marignier, Diego Franciotta, Klemens Ruprecht, Bettina Kuenz, Paulus Rommer, Wolfgang Kristoferitsch, Brigitte Wildemann, Angela Vincent

122 Citations (Scopus)

Abstract

Background: Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. Objective: To assess the frequency of AQP4-Ab in patients with optic neuritis (ON), and to investigate the prognostic implications of AQP4-Ab seropositivity in such patients. Patients and methods: AQP4-Ab serum levels were determined in 224 individuals from Austria, Denmark, France, Germany, Italy, and Turkey using a newly developed fluorescence immunoprecipitation assay employing recombinant human AQP4. Results: AQP4-Ab were detectable in 8/139 (5.8%) patients with acute monosymptomatic optic neuritis (AMON) and in 10/17 (58.8%) patients with established NMO and a last relapse of acute ON (NMO/ON), but not in 32 patients with multiple sclerosis or in 36 healthy controls. At last examination, 4/8 (50%) seropositive AMON patients had met the criteria for NMO but 0/128 seronegative AMON patients. Disease severity differed significantly between seropositive and seronegative AMON. Complete bilateral or unilateral blindness occurred in six AQP4-Ab positive patients, but only in one AQP4-Ab negative patient. AQP4-Ab levels did not vary between seropositive AMON and NMO/ON and did not correlate with disease severity. Female gender, a relapsing course, and concomitant autoimmunity were associated with AQP4-Ab seropositive status and risk of developing NMO. Conclusion: AQP4-Ab is relatively rare among patients with AMON, but if present it predicts a high rate of conversion to NMO within one year.

Original language	English
Journal	Journal of the Neurological Sciences
Volume	298
Issue number	1-2
Pages (from-to)	158-62
Number of pages	5
ISSN	0022-510X
DOIs	https://doi.org/10.1016/j.jns.2010.07.011
Publication status	Published - 15 Nov 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jns.2010.07.011

Cite this

Jarius, S., Frederiksen, J. L. B., Waters, P., Paul, F., Akman-Demir, G., Marignier, R., Franciotta, D., Ruprecht, K., Kuenz, B., Rommer, P., Kristoferitsch, W., Wildemann, B., & Vincent, A. (2010). Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 298(1-2), 158-62. https://doi.org/10.1016/j.jns.2010.07.011

Jarius, S, Frederiksen, JLB, Waters, P, Paul, F, Akman-Demir, G, Marignier, R, Franciotta, D, Ruprecht, K, Kuenz, B, Rommer, P, Kristoferitsch, W, Wildemann, B & Vincent, A 2010, 'Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis', Journal of the Neurological Sciences, vol. 298, no. 1-2, pp. 158-62. https://doi.org/10.1016/j.jns.2010.07.011

@article{e195c421b6c9410f88985d6a4e48ca93,

title = "Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis",

abstract = "Background: Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. Objective: To assess the frequency of AQP4-Ab in patients with optic neuritis (ON), and to investigate the prognostic implications of AQP4-Ab seropositivity in such patients. Patients and methods: AQP4-Ab serum levels were determined in 224 individuals from Austria, Denmark, France, Germany, Italy, and Turkey using a newly developed fluorescence immunoprecipitation assay employing recombinant human AQP4. Results: AQP4-Ab were detectable in 8/139 (5.8%) patients with acute monosymptomatic optic neuritis (AMON) and in 10/17 (58.8%) patients with established NMO and a last relapse of acute ON (NMO/ON), but not in 32 patients with multiple sclerosis or in 36 healthy controls. At last examination, 4/8 (50%) seropositive AMON patients had met the criteria for NMO but 0/128 seronegative AMON patients. Disease severity differed significantly between seropositive and seronegative AMON. Complete bilateral or unilateral blindness occurred in six AQP4-Ab positive patients, but only in one AQP4-Ab negative patient. AQP4-Ab levels did not vary between seropositive AMON and NMO/ON and did not correlate with disease severity. Female gender, a relapsing course, and concomitant autoimmunity were associated with AQP4-Ab seropositive status and risk of developing NMO. Conclusion: AQP4-Ab is relatively rare among patients with AMON, but if present it predicts a high rate of conversion to NMO within one year.",

author = "Sven Jarius and Frederiksen, {Jette Lautrup Battistini} and Patrick Waters and Friedemann Paul and Gulsen Akman-Demir and Romain Marignier and Diego Franciotta and Klemens Ruprecht and Bettina Kuenz and Paulus Rommer and Wolfgang Kristoferitsch and Brigitte Wildemann and Angela Vincent",

year = "2010",

month = nov,

day = "15",

doi = "10.1016/j.jns.2010.07.011",

language = "English",

volume = "298",

pages = "158--62",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis

AU - Jarius, Sven

AU - Frederiksen, Jette Lautrup Battistini

AU - Waters, Patrick

AU - Paul, Friedemann

AU - Akman-Demir, Gulsen

AU - Marignier, Romain

AU - Franciotta, Diego

AU - Ruprecht, Klemens

AU - Kuenz, Bettina

AU - Rommer, Paulus

AU - Kristoferitsch, Wolfgang

AU - Wildemann, Brigitte

AU - Vincent, Angela

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Background: Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. Objective: To assess the frequency of AQP4-Ab in patients with optic neuritis (ON), and to investigate the prognostic implications of AQP4-Ab seropositivity in such patients. Patients and methods: AQP4-Ab serum levels were determined in 224 individuals from Austria, Denmark, France, Germany, Italy, and Turkey using a newly developed fluorescence immunoprecipitation assay employing recombinant human AQP4. Results: AQP4-Ab were detectable in 8/139 (5.8%) patients with acute monosymptomatic optic neuritis (AMON) and in 10/17 (58.8%) patients with established NMO and a last relapse of acute ON (NMO/ON), but not in 32 patients with multiple sclerosis or in 36 healthy controls. At last examination, 4/8 (50%) seropositive AMON patients had met the criteria for NMO but 0/128 seronegative AMON patients. Disease severity differed significantly between seropositive and seronegative AMON. Complete bilateral or unilateral blindness occurred in six AQP4-Ab positive patients, but only in one AQP4-Ab negative patient. AQP4-Ab levels did not vary between seropositive AMON and NMO/ON and did not correlate with disease severity. Female gender, a relapsing course, and concomitant autoimmunity were associated with AQP4-Ab seropositive status and risk of developing NMO. Conclusion: AQP4-Ab is relatively rare among patients with AMON, but if present it predicts a high rate of conversion to NMO within one year.

AB - Background: Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. Objective: To assess the frequency of AQP4-Ab in patients with optic neuritis (ON), and to investigate the prognostic implications of AQP4-Ab seropositivity in such patients. Patients and methods: AQP4-Ab serum levels were determined in 224 individuals from Austria, Denmark, France, Germany, Italy, and Turkey using a newly developed fluorescence immunoprecipitation assay employing recombinant human AQP4. Results: AQP4-Ab were detectable in 8/139 (5.8%) patients with acute monosymptomatic optic neuritis (AMON) and in 10/17 (58.8%) patients with established NMO and a last relapse of acute ON (NMO/ON), but not in 32 patients with multiple sclerosis or in 36 healthy controls. At last examination, 4/8 (50%) seropositive AMON patients had met the criteria for NMO but 0/128 seronegative AMON patients. Disease severity differed significantly between seropositive and seronegative AMON. Complete bilateral or unilateral blindness occurred in six AQP4-Ab positive patients, but only in one AQP4-Ab negative patient. AQP4-Ab levels did not vary between seropositive AMON and NMO/ON and did not correlate with disease severity. Female gender, a relapsing course, and concomitant autoimmunity were associated with AQP4-Ab seropositive status and risk of developing NMO. Conclusion: AQP4-Ab is relatively rare among patients with AMON, but if present it predicts a high rate of conversion to NMO within one year.

U2 - 10.1016/j.jns.2010.07.011

DO - 10.1016/j.jns.2010.07.011

M3 - Journal article

SN - 0022-510X

VL - 298

SP - 158

EP - 162

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

IS - 1-2

ER -

Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this